Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a novel target for liver cancer therapy by Wadhwa, R et al.
Title Mortalin-p53 interaction in cancer cells is stress dependent andconstitutes a novel target for liver cancer therapy
Author(s) Lu, WJ; Lee, NP; Kaul, SC; Poon, RT; Wadhwa, R; Luk, JM
Citation
The 46th Annual Meeting of the European Association for the
Study of the Liver ( International Liver Congress™ 2011), Berlin,
Germany, 30 March-3 April 2011. In Journal of Hepatology, 2011,
v. 54 suppl. 1, p. S272, abstract no. 676
Issued Date 2011
URL http://hdl.handle.net/10722/137900
Rights
NOTICE: this is the author’s version of a work that was accepted
for publication in Journal of Hepatology. Changes resulting from
the publishing process, such as peer review, editing,
corrections, structural formatting, and other quality control
mechanisms may not be reflected in this document. Changes
may have been made to this work since it was submitted for
publication. A definitive version was subsequently published in
Journal of Hepatology, v. 54, suppl. 1 (March 2011). DOI:
10.1016/S0168-8278(11)60678-8
MORTALIN-P53 INTERACTION IN CANCER CELLS IS STRESS DEPENDENT AND 
CONSTITUTES A NOVEL TARGET FOR LIVER CANCER THERAPY 
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BACKGROUND AND AIMS: The mortality rate of HCC is high due to tumor recurrence and 
lack of effective treatment. By proteomics analysis of matched tumor and non-tumor tissues, 
mortalin was identified as a marker for hepatocellular carcinoma (HCC) metastasis and 
recurrence, suggesting its tight link in HCC development and recurrence. The aim of this study is 
to examine the role of mortalin in hepatocarcinogenesis. METHODS: The mortalin expression 
was examined in 100 HCC patients by IHC staining and western blotting. The clinical parameters 
were analyzed by SPSS. The mortalin specific shRNA was constructed for the loss function 
investigation. The apoptotic cell was detected by In Suit Tunel staining. The interaction of 
Mortalin and p53 in liver cancer cell-line was examined by CoIP assay. The location of mortalin 
and p53 were observed by immunofluorescence staining. RESULTS: Mortalin was overexpressed 
in the 61% of clinical samples. The clinical-pathology analysis showing its tight link with HCC 
recurrence (p = 0.005) and the microsatellite formation (p = 0.028), a crucial feature of intra-
hepatic metastasis. The further functional investigation has shown that unlike most of the cancer 
cells, HepG2 hepatoma lacked mortalin-p53 interaction and is resistant to apoptosis induced in 
response to knockdown of mortalin expression. Furthermore, the mortalin-shRNA-sensitive HCC 
cells show a higher degree of p53 phosphorylation. Since phosphorylation in p53 is a sign for 
genotoxic stress, we treated HepG2 cells with Cisplatin at sub-lethal concentrations and 
demonstrated that under these conditions p53 is (i) phosphorylated at the critical site, (ii) can be 
co-precipitated with mortalin, and (iii) apoptosis is induced by mortalin-shRNA. Again, the 
mortalin shRNA induced apoptosis can be rescued by p53-shRNA or p53 inhibitor. Mortalin 
knock-down also sensitizes the cancer cells to H2O2 and Doxorubicin induced stress. When the 
interaction of mortalin with p53 was challenged with a chemical or peptide inhibitor, apoptosis is 
induced in the mortalin-shRNA sensitive cells and in the non-sensitive cells but only in the 
presence of stress inducing reagents. CONCLUSIONS: Mortalin-p53 interaction is part of a cell 
stress response, which impairs p53 apoptotic ability in HCC cells. Targeting mortalin-p53 
interaction is a promising strategy for HCC therapy. 
